Guardant Health Selected by Abu Dhabi Health Department to Launch Colorectal Cancer Screening Program

MT Newswires Live01-30

Guardant Health (GH) said Thursday it signed an agreement with the Abu Dhabi Public Health Center to launch a blood-based colorectal cancer screening using the Shield test.

Hikma Pharmaceuticals, a regional partner for Guardant in the Middle East and North Africa, arranged the deal, which will be implemented by the M42 healthcare system, the company said.

The Shield test will be included in Abu Dhabi Public Health Center's IFHAS screening program and will be offered at facilities run by Ambulatory Healthcare Services and M42 across Abu Dhabi, Al Ain, and the Al Dhafra region, Guardant added.

Organizers expect the program to screen roughly 10,000 individuals during its first year, according to the oncology company.

Financial details were not disclosed.

Shares of the company were up about 3.7% in recent trading.

Price: 49.43, Change: +1.78, Percent Change: +3.74

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2507627111?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-30 23:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507627111","market":"us","top_or_hot":-1,"title":"Guardant Health Selected by Abu Dhabi Health Department to Launch Colorectal Cancer Screening Program","media":"MT Newswires Live","content":"<html><body><p> Guardant Health (GH) said Thursday it signed an agreement with the Abu Dhabi Public Health Center to launch a blood-based colorectal cancer screening using the Shield test.</p><p>Hikma Pharmaceuticals, a regional partner for Guardant in the Middle East and North Africa, arranged the deal, which will be implemented by the M42 healthcare system, the company said.</p><p>The Shield test will be included in Abu Dhabi Public Health Center's IFHAS screening program and will be offered at facilities run by Ambulatory Healthcare Services and M42 across Abu Dhabi, Al Ain, and the Al Dhafra region, Guardant added.</p><p>Organizers expect the program to screen roughly 10,000 individuals during its first year, according to the oncology company.</p><p>Financial details were not disclosed.</p><p>Shares of the company were up about 3.7% in recent trading.</p><p>Price: 49.43, Change: +1.78, Percent Change: +3.74</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health Selected by Abu Dhabi Health Department to Launch Colorectal Cancer Screening Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health Selected by Abu Dhabi Health Department to Launch Colorectal Cancer Screening Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-30 23:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Guardant Health (GH) said Thursday it signed an agreement with the Abu Dhabi Public Health Center to launch a blood-based colorectal cancer screening using the Shield test.Hikma Pharmaceuticals, a ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507627111","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507627111","pubTimestamp":1738251853,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guardant Health  said Thursday it signed an agreement with the Abu Dhabi Public Health Center to launch a blood-based colorectal cancer screening using the Shield test.Hikma Pharmaceuticals, a regional partner for Guardant in the Middle East and North Africa, arranged the deal, which will be implemented by the M42 healthcare system, the company said.The Shield test will be included in Abu Dhabi Public Health Center's IFHAS screening program and will be offered at facilities run by Ambulatory Healthcare Services and M42 across Abu Dhabi, Al Ain, and the Al Dhafra region, Guardant added.Organizers expect the program to screen roughly 10,000 individuals during its first year, according to the oncology company.Financial details were not disclosed.Shares of the company were up about 3.7% in recent trading.Price: 49.43, Change: +1.78, Percent Change: +3.74","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","GH":"Guardant Health Inc.","BK4196":"保健护理服务","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4585":"ETF&股票定投概念"},"translate_title":"Guardant Health被阿布扎比卫生部选中启动结直肠癌筛查项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":0.9},"content_text":"Guardant Health (GH) said Thursday it signed an agreement with the Abu Dhabi Public Health Center to launch a blood-based colorectal cancer screening using the Shield test.Hikma Pharmaceuticals, a regional partner for Guardant in the Middle East and North Africa, arranged the deal, which will be implemented by the M42 healthcare system, the company said.The Shield test will be included in Abu Dhabi Public Health Center's IFHAS screening program and will be offered at facilities run by Ambulatory Healthcare Services and M42 across Abu Dhabi, Al Ain, and the Al Dhafra region, Guardant added.Organizers expect the program to screen roughly 10,000 individuals during its first year, according to the oncology company.Financial details were not disclosed.Shares of the company were up about 3.7% in recent trading.Price: 49.43, Change: +1.78, Percent Change: +3.74","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2507627111"}